- Home
- BNR vs IGC Comparison
BNR vs IGC Comparison
Compare BNR & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- IGC
- Stock Information
- Founded
- BNR 2014
- IGC 2005
- Country
- BNR China
- IGC United States
- Employees
- BNR N/A
- IGC N/A
- Industry
- BNR Medical Specialities
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- BNR Health Care
- IGC Health Care
- Exchange
- BNR Nasdaq
- IGC Nasdaq
- Market Cap
- BNR 38.3M
- IGC 39.8M
- IPO Year
- BNR 2020
- IGC N/A
- Fundamental
- Price
- BNR N/A
- IGC $0.42
- Analyst Decision
- BNR
- IGC Strong Buy
- Analyst Count
- BNR 0
- IGC 2
- Target Price
- BNR N/A
- IGC $4.00
- AVG Volume (30 Days)
- BNR 24.0K
- IGC 695.2K
- Earning Date
- BNR 09-08-2025
- IGC 11-11-2025
- Dividend Yield
- BNR N/A
- IGC N/A
- EPS Growth
- BNR N/A
- IGC N/A
- EPS
- BNR N/A
- IGC N/A
- Revenue
- BNR $74,862,782.00
- IGC $1,327,000.00
- Revenue This Year
- BNR $136.32
- IGC $15.26
- Revenue Next Year
- BNR N/A
- IGC $3.41
- P/E Ratio
- BNR N/A
- IGC N/A
- Revenue Growth
- BNR 5.20
- IGC 24.95
- 52 Week Low
- BNR $2.18
- IGC $0.25
- 52 Week High
- BNR $11.12
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- BNR N/A
- IGC 52.73
- Support Level
- BNR N/A
- IGC $0.39
- Resistance Level
- BNR N/A
- IGC $0.43
- Average True Range (ATR)
- BNR 0.00
- IGC 0.02
- MACD
- BNR 0.00
- IGC -0.00
- Stochastic Oscillator
- BNR 0.00
- IGC 44.42
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.